Brokerage firm Baird Maintains its rating on Cooper Companies Inc(NYSE:COO). In a research note issued to the investors, the brokerage major Raises the price-target to $196.00 per share. The shares have been rated Outperform. The rating by Baird was issued on Aug 18, 2016.
In a different note, JP Morgan said it Initiates Coverage on Cooper Companies Inc, according to a research note issued on Jul 13, 2016. The shares have been rated ‘Buy’ by the firm. On Jun 3, 2016, Jefferies said it Maintains its rating on Cooper Companies Inc. In the research note, the firm Raises the price-target to $175.00 per share. The shares have been rated ‘Buy’ by the firm.
Cooper Companies Inc (COO) made into the market gainers list on Mondays trading session with the shares advancing 1.44% or 2.64 points. Due to strong positive momentum, the stock ended at $186.56, which is also near the day’s high of $186.84. The stock began the session at $184.29 and the volume stood at 3,71,853 shares. The 52-week high of the shares is $189.76 and the 52 week low is $119.28. The company has a current market capitalization of $9,039 M and it has 4,84,48,341 shares in outstanding.
Cooper Companies Inc(COO) last announced its earnings results on Jun 2, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $483.79M. Analysts had an estimated revenue of $463.99M. Earnings per share were $2.05. Analysts had estimated an EPS of $1.91.
Several Insider Transactions has been reported to the SEC. On Jul 12, 2016, Michael Kalkstein (director) sold 1,000 shares at $178.55 per share price.Also, On Jun 29, 2016, Stanley Md Zinberg (director) sold 10,000 shares at $170.00 per share price.On Jun 29, 2016, Randal Golden (VP, General Counsel) sold 2,000 shares at $167.31 per share price, according to the Form-4 filing with the securities and exchange commission.
The Cooper Companies Inc. (Cooper) is a global medical device company. The Company operates through two business units CooperVision Inc. (CVI) and CooperSurgical Inc. (CSI). CooperVision is a global manufacturer providing products for contact lens wearers. CooperSurgical focuses on supplying women’s health clinicians with products and treatment options to improve the delivery of healthcare to women. CooperSurgical products fall into three main segments based on the point of healthcare delivery: Hospital Office and Fertility Clinic. CooperVision develops manufactures and markets a range of monthly two-week and single-use contact lenses featuring advanced materials and optics. CooperVision is involved in correcting vision problems such as astigmatism presbyopia and ocular dryness and provides innovative contact lens solutions. The CooperVision Companys brands include Biofinity Avaira and MyDay and CooperSurgical Companys brands include Advincula Arch SeeClear and Mobius.